Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PremiÈRe: preoperative elacestrant with or without ovarian function suppression in premenopausal luminal breast cancer
2023-503373-37-01Phase 2Authorised
- Sponsor
- SOLTI
- Start
- Jul 2023
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elacestrant in breast cancer (3 arms), sponsored by SOLTI. Planned start Jul 2023; status: authorised.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-503373-37-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503373-37-01.